You don't need to be Socrates to see that holding this is a losing proposition.
When you think about the following, just how little is destined to trickle to ACR, makes a lot of sense:
- Divide by 2 to account for rebates & chargebacks demanded by the end-customer (paid for by the pharma co.).
- Divide by 2 again, to account for sales-costs.
- Divide by 2 again, to account for partner's share.
- Divide by 5 to account for competitors.
And then consider that ACR's partners are small compared to competitors (Teva, Viatris, Sandoz, Amneal, Dr Reddys, Aurobindo, Endo etc) who will get the lion's share.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $7.366M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 883823 | 1.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.8¢ | 500697 | 1 |
View Market Depth
| Last trade - 16.21pm 30/07/2025 (20 minute delay) ? |
| ACR (ASX) Chart |
Day chart unavailable